Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study-Reference-Cited by-同舟云学术

Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study

Published:2019-03-28 Issue: Volume: Page:
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Zhou Li¹,Tong Xiao¹,Sharma Pradeep²,Xu Hongmei¹,Al‐Huniti Nidal¹,Zhou Diansong¹

Affiliation:

1. Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit AstraZeneca Boston Massachusetts

2. Mechanistic Safety and ADME Sciences, Drug Safety and Metabolism, IMED Biotech Unit AstraZeneca Cambridge UK

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13209

Reference28 articles.

1. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state

2. Renal drug transporters and their significance in drug–drug interactions

3. US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States

4. Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance

5. Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Physiologically Based Pharmacokinetic Model to Delineate the Impact of Aging and Renal Impairment on Ceftazidime Clearance;Antibiotics;2024-09-09

2. Ceftazidime and Usnic Acid Encapsulated in Chitosan-Coated Liposomes for Oral Administration against Colorectal Cancer-Inducing Escherichia coli;Pharmaceuticals;2024-06-19

3. The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine;Pharmaceutics;2024-04-02

4. An Application of a Physiologically Based Pharmacokinetic Approach to Predict Ceftazidime Pharmacokinetics in a Pregnant Population;Pharmaceutics;2024-03-28

5. Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models;Expert Opinion on Drug Metabolism & Toxicology;2024-01-31